GSK plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Luke Victor Miels
- Full Time Employees
- 66,841
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 79 New Oxford Street London GL United Kingdom WC1A 1DG
- IPO Date
- Mar 28, 1980
- CIK
- 0001131399
- Website
- gsk.com
- Similar Companies
- Business
- GSK plc is a British multinational biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and specialty therapies focused on respiratory/immunology, oncology, HIV and infectious diseases. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, the company is headquartered at 79 New Oxford Street in London, England, and operates globally with manufacturing sites in 37 countries, delivering products to markets including the US, Europe, Asia and emerging regions. Its core portfolio encompasses specialty medicines such as Nucala (mepolizumab) for severe eosinophilic asthma, COPD and CRSwNP; Jemperli (dostarlimab) for endometrial cancer; Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy and Shingrix vaccines for RSV and shingles respectively; a broad range of over 20 vaccines targeting meningococcal disease (e.g. Penmenvy, a 5-in-1 MenABCWY vaccine), HPV, hepatitis and influenza; HIV treatments via ViiV Healthcare including long-acting injectables like Cabenuva (cabotegravir + rilpivirine), Apretude for PrEP and investigational assets like N6LS; general medicines including inhalers for asthma/COPD, antibiotics and gepotidacin (Blujepa) for UTIs; and oncology offerings like Zejula (niraparib) for ovarian cancer. In recent developments, GSK completed the $1.15 billion acquisition of IDRx Inc. in 2025 to advance IDRX-42, a next-generation KIT inhibitor for GIST adding to its GI cancer portfolio; entered a potential $12 billion alliance with Hengrui Pharma paying $500 million upfront for rights to a COPD candidate and up to 11 respiratory, immunology and oncology programs outside greater China; acquired exclusive rights from Syndivia for a prostate cancer antibody-drug conjugate; launched or gained approvals for five new products/line extensions in 2025 including Penmenvy, Blujepa, Nucala for COPD and depemokimab (under FDA/EMA review as the first 6-month ultra-long-acting biologic for type 2 asthma and CRSwNP); announced a $30 billion US investment over five years including a $1.2 billion biologics facility in Pennsylvania; established the GSK-Oxford Cancer Immuno-Prevention Programme; and relocated its headquarters to central London while preparing for CEO transition to Luke Miels in 2026.
Company News
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
GSK to Advance mRNA Influenza Vaccine Into Phase III Development
Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK to advance mRNA flu vaccine to late-stage trial
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Hold” from Brokerages
GSK: Still One Of My Top Healthcare Picks
Noetik Achieves First Milestone in Landmark GSK Collaboration
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy
GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth
GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth